H E Heslop

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint Gene therapy
    H E Heslop
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Cytotherapy 9:519-20. 2007
  2. pmc How I treat EBV lymphoproliferation
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 114:4002-8. 2009
  3. pmc Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 115:925-35. 2010
  4. ncbi request reprint Gene and cell transfer for specific immunotherapy
    M K Brenner
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Vox Sang 74:87-90. 1998
  5. ncbi request reprint Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 39:677-86. 2007
  6. ncbi request reprint Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab
    R Lamba
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 36:797-802. 2005
  7. ncbi request reprint Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma
    B Gahn
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Int J Cancer 93:706-13. 2001
  8. pmc Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
    V Hoyos
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 24:1160-70. 2010
  9. ncbi request reprint Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, 77030, USA
    Bone Marrow Transplant 36:1001-8. 2005
  10. ncbi request reprint Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients
    B Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Transplantation 72:1078-86. 2001

Research Grants

  1. Enhancing T Cell Therapy of Cancer
    Helen Heslop; Fiscal Year: 2006
  2. Training in Cell and Gene Therapy
    Helen Heslop; Fiscal Year: 2007

Collaborators

Detail Information

Publications98

  1. ncbi request reprint Gene therapy
    H E Heslop
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Cytotherapy 9:519-20. 2007
  2. pmc How I treat EBV lymphoproliferation
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 114:4002-8. 2009
    ..Major challenges remain for defining indications for preemptive therapies and integrating novel and conventional therapies...
  3. pmc Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 115:925-35. 2010
    ....
  4. ncbi request reprint Gene and cell transfer for specific immunotherapy
    M K Brenner
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Vox Sang 74:87-90. 1998
    ..In a number of settings, gene modified tumor vaccines, cytotoxic T cells and dendritic cells are producing both immunomodulation and clinically evident benefits. Continued exploration of this approach seems well justified...
  5. ncbi request reprint Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 39:677-86. 2007
    ..In conclusion, recipients of alternative donor transplants at our institution have significantly delayed adv-specific cellular immune recovery, which correlates to an increased risk of adv-associated morbidity and mortality...
  6. ncbi request reprint Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab
    R Lamba
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 36:797-802. 2005
    ..However, in the majority of patients, infection is transient, and antiviral T cell reconstitution is rapid. Monitoring with CMV-specific CTLs may help identify the subset of patients at risk from recurrent infection or disease...
  7. ncbi request reprint Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma
    B Gahn
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Int J Cancer 93:706-13. 2001
    ..Hence, recombinant adenoviruses encoding LMP2A effectively transduce DCs and direct the generation of LMP2A-specific CTLs. This approach will be a potent strategy in Hodgkin's lymphoma immunotherapy...
  8. pmc Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
    V Hoyos
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 24:1160-70. 2010
    ..In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies...
  9. ncbi request reprint Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, 77030, USA
    Bone Marrow Transplant 36:1001-8. 2005
    ..This work will help in identifying at-risk populations for our upcoming immunotherapy trial using adoptively transferred donor-derived adenovirus-specific cytotoxic T lymphocytes...
  10. ncbi request reprint Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients
    B Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Transplantation 72:1078-86. 2001
    ....
  11. ncbi request reprint Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)
    U Popat
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX, USA
    Bone Marrow Transplant 37:547-52. 2006
    ..Hence, RISCT using lymphodepleting antibodies may be of value for older patients with AML, even in those with active or high-risk disease, and even if they lack an MHC-identical sibling donor...
  12. ncbi request reprint EBV specific CTL: a model for immune therapy
    C M Rooney
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Vox Sang 74:497-8. 1998
    ..We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value...
  13. ncbi request reprint Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation
    T Vu
    Center for Cell and Gene Therapy, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 39:705-9. 2007
    ..Given this high incidence of HHV-6 and the possibility of successful outcome with prompt treatment, a high index of suspicion of this disorder is required in recipients of monoclonal antibody supported allografts...
  14. ncbi request reprint T cell therapies
    S Gottschalk
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3 3320, 77030 Houston, USA
    Ernst Schering Found Symp Proc . 2006
    ..Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens...
  15. pmc Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences
    M A Pule
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Cytotherapy 10:526-39. 2008
    ..At present, most measures to assess IHJ are complex, insensitive and may be subject to IHJ selection bias inherent to the technology used...
  16. doi request reprint Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen
    Alana A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1245-52. 2008
    ..For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD...
  17. ncbi request reprint Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation
    R T Kamble
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    Bone Marrow Transplant 40:563-6. 2007
    ..CI of HHV-6 may confound the interpretation of HHV-6 viremia after stem cell transplantation; consideration of the possibility of CI HHV-6 will avoid unnecessary antiviral therapy...
  18. ncbi request reprint Gene therapy for paediatric leukaemia
    R F Rousseau
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Expert Opin Biol Ther 1:663-74. 2001
    ..With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of paediatric leukaemia in the future...
  19. pmc Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution
    J A Shafer
    Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Leuk Lymphoma 51:664-70. 2010
    ..Our data show encouraging outcomes for patients with chemosensitive relapsed HL who receive hematopoietic stem cell transplant (HSCT) and support the value of the procedure even when the disease is chemoresistant...
  20. pmc Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
    A E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 24:563-72. 2010
    ..Hence, malignant B cells with a primary drug-resistant phenotype can be targeted by T- cell-mediated effector activity after immunization of human subjects...
  21. ncbi request reprint T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients
    A M Leen
    Center for Cell and Gene Therapy, Department of Pediatrics Hem Onc, Baylor College of Medicine, 6621 Fannin St, MC3 3320 Houston, TX 77030, USA
    Ann N Y Acad Sci 1062:104-15. 2005
    ..Thus, we have characterized human T-cell responses to adenovirus in vitro and explored the potential of adoptive T-cell immunotherapy as a prophylactic or therapeutic strategy for adenovirus infections posttransplant...
  22. ncbi request reprint Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia
    Alana A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:1277-84. 2006
    ..We conclude that, for children with SAA, AD transplantation is as effective as MSD transplantation. Further, compared with ATG, preparatory regimens containing Campath may be associated with a lower incidence of extensive, chronic GHVD...
  23. pmc The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
    C Arber
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Gene Ther 20:958-62. 2013
    ..These results suggest that exposure to viral-derived 2A sequences is unlikely to produce unwanted T cell responses in immunocompetent individuals and further supports their continued use for studies of human gene therapy...
  24. ncbi request reprint Options for T-cell based therapies
    H E Heslop
    Center for Gene and Cell Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Vox Sang 87:230-4. 2004
  25. ncbi request reprint Immunotherapy for Hodgkin's disease
    C M Rooney
    Centre for Cell and Gene Therapy, Department of Pediatrics, Division of Hematology and Oncology, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
    Ann Hematol 81:S39-42. 2002
    ..Future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies...
  26. ncbi request reprint Gene-marking studies of hematopoietic cells
    C M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Int J Hematol 73:14-22. 2001
    ..With continuing advances in gene-marking technology, the value of the information provided by these studies increases, thereby ensuring their continued relevance to the field of gene transfer...
  27. ncbi request reprint Gene therapy of pediatric leukemia
    H E Heslop
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Lab Med 20:183-95, x. 2000
    ..Some of these approaches are now being evaluated in clinical trials...
  28. ncbi request reprint Efficient infection of primitive hematopoietic stem cells by modified adenovirus
    P Yotnda
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Gene Ther 8:930-7. 2001
    ..The ability of Ad5/F35 to deliver transgenes to primitive HPC with high efficiency and low toxicity in the absence of growth factors provides an improved means of studying the consequences of transient gene expression in these cells...
  29. ncbi request reprint Is retroviral gene marking too dangerous to use?
    M K Brenner
    Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Cytotherapy 5:190-3. 2003
  30. pmc Immunotherapy targeting EBV-expressing lymphoproliferative diseases
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Best Pract Res Clin Haematol 21:405-20. 2008
    ..A number of strategies to genetically modify the infused T cells and modulate the host environment are under evaluation...
  31. ncbi request reprint Regression of experimental medulloblastoma following transfer of HER2-specific T cells
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, The Methodist Hospital, Houston, Texas 77030, USA
    Cancer Res 67:5957-64. 2007
    ..In contrast, delivery of nontransduced T cells did not change the tumor growth pattern. Adoptive transfer of HER2-specific T cells may represent a promising immunotherapeutic approach for medulloblastoma...
  32. doi request reprint Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
    J E Cox
    Department of Pharmacy, Center for Cell and Gene Therapy, The Methodist Hospital, Houston, TX, USA
    Bone Marrow Transplant 49:219-22. 2014
    ....
  33. ncbi request reprint Adoptive cellular immunotherapy for viral diseases
    Y Fujita
    Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Bone Marrow Transplant 41:193-8. 2008
    ..Current efforts are focused on providing protection toward a broader range of viruses safely, rapidly and effectively...
  34. pmc Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
    Ann M Leen
    Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, TX 77030, USA
    Blood 114:4283-92. 2009
    ..This trial was registered at www.clinicaltrials.gov as #NCT00590083...
  35. ncbi request reprint In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Leuk Lymphoma 47:837-42. 2006
    ....
  36. pmc Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 110:2793-802. 2007
    ..We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach...
  37. pmc Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation
    Siok Keen Tey
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:913-24. 2007
    ..We have demonstrated the clinical feasibility of this approach after haploidentical transplantation by scaling up production using clinical grade materials...
  38. pmc Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
    Biagio De Angelis
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 114:4784-91. 2009
    ....
  39. pmc Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
    Chrystal U Louis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 113:2442-50. 2009
    ..Lymphodepleting mAbs prior CTL transfer may represent an alternative to chemotherapy to enhance expansion of infused CTL. This study is registered at (http://www.clinialtrials.gov) as NCT00608257...
  40. pmc Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy
    Yuriko Fujita
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX 77030, USA
    J Immunother 31:665-74. 2008
    ..By simultaneously expanding a portion of the selected product, we can characterize phenotype and function of the infused product and link them with subsequent in vivo outcome...
  41. ncbi request reprint Prompt versus preemptive intervention for EBV lymphoproliferative disease
    Hans Joachim Wagner
    Departments of Pediatrics and Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 103:3979-81. 2004
    ..Hence, quantitative measurement of EBV DNA may best be used to enable the prompt rather than the preemptive treatment of PTLD...
  42. doi request reprint Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation
    Yu Feng Lin
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 56:143-51. 2011
    ..In a retrospective study, we compared allogeneic PBSCT (n = 30) with BMT (n = 110) in children with acute leukemia between January 2001 and September 2006...
  43. ncbi request reprint Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection
    Barbara Savoldo
    Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 100:4059-66. 2002
    ....
  44. pmc T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
    Juan Vera
    Center for Cell and Gene Therapy, Baylor College of Medicine, Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 108:3890-7. 2006
    ....
  45. doi request reprint Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine
    Nabil Ahmed
    Center for Cell and Gene Therapy, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1298-304. 2008
    ..Thus, the regimen that we describe can be used with minimal toxicity to effectively overcome graft failure after myeloablative HSCT in children...
  46. ncbi request reprint Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes
    Karin C M Straathof
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
    Blood 105:1898-904. 2005
    ..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
  47. ncbi request reprint Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hosptial and Texas Children s Hospital, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 17:401-13. 2004
    ..The use of genetically modified T cells or newer suicide genes may result in improved safety and efficacy. Current challenges are to define indications for immunotherapy or antibody therapy in patients with incipient or overt PTLD...
  48. pmc Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2838-45. 2007
    ..This study is registered at http://www.cancer.gov/clinicaltrials (protocol IDs: BCM-H-9936, NCT00062868, NCT00070226)...
  49. ncbi request reprint Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, Texas, USA
    Am J Transplant 5:566-72. 2005
    ..Rituximab effectively induced regression of PTLD in OLT recipients. However, EBV-specific T-cell immunocompetence, which may be crucial for the long-term control of EBV-mediated proliferation, did not improve...
  50. pmc HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 16:474-85. 2010
    ....
  51. pmc Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
    Kenneth P Micklethwaite
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 115:2695-703. 2010
    ..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse...
  52. pmc An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies
    Carlos Almeida Ramos
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas, USA
    Stem Cells 28:1107-15. 2010
    ..We believe that this approach will become of increasing value as clinical applications for MSCs develop further...
  53. ncbi request reprint Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas
    Zhensheng Liu
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Recent Results Cancer Res 159:123-33. 2002
    ....
  54. ncbi request reprint Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Acta Haematol 110:139-48. 2003
    ..The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated...
  55. pmc The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia
    Yu Feng Lin
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 16:1272-81. 2010
    ..More studies using larger and randomized controlled trials are needed to confirm the long-term cost-effectiveness of each procedure...
  56. pmc T-cell-based therapies for malignancy and infection in childhood
    Nabil Ahmed
    Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates Street, Suite 1770, MC3 3320, Houston, TX 77030, USA
    Pediatr Clin North Am 57:83-96. 2010
    ....
  57. ncbi request reprint CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors
    U Popat
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Bone Marrow Transplant 35:1127-32. 2005
    ....
  58. ncbi request reprint Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses
    P Yotnda
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Hum Gene Ther 15:1229-42. 2004
    ..Ad5F/K21 and Ad5F/RGD should be of value for the genetic modification of human primary leukemia cells...
  59. doi request reprint Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis
    S H Appel
    Department of Neurology, Methodist Neurological Institute, Houston, TX 77030, USA
    Neurology 71:1326-34. 2008
    ..Amyotrophic lateral sclerosis (ALS), an inexorably progressive motoneuron disease, is accompanied by significantly increased markers of inflammation. These inflammatory constituents could protect, harm, do neither, or do both...
  60. ncbi request reprint Immune therapy for EBV infections after hemopoietic stem-cell transplant
    H E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston TX 77030, USA
    Cytotherapy 4:433-4. 2002
  61. ncbi request reprint Adoptive immunotherapy for posttransplantation viral infections
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 10:143-55. 2004
    ..The use of genetically modified T cells or the use of newer suicide genes may result in improved safety and efficacy...
  62. ncbi request reprint Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy
    Robert A Krance
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:273-81. 2003
    ..The in vivo myeloreductive and lymphoreductive properties of lytic CD45 MAb in humans, therefore, closely parallel the activity seen in a murine model and, therefore, may be of similar value...
  63. pmc T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Blood 113:6392-402. 2009
    ..This approach may be of value in patients affected by HL...
  64. pmc Adoptive T cell therapy of cancer
    Malcolm K Brenner
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Curr Opin Immunol 22:251-7. 2010
    ..Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment...
  65. ncbi request reprint Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia
    Uday Popat
    Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Treat Rev 29:3-10. 2003
    ..Relapse remains the major cause of transplant failure and immunotherapy strategies post-transplant to augment the graft versus leukaemia effect are being explored...
  66. ncbi request reprint Immunotherapy for Epstein-Barr virus-associated cancers in children
    Karin C M Straathof
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Oncologist 8:83-98. 2003
    ..If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens...
  67. ncbi request reprint Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation
    Hans Joachim Wagner
    Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas, USA
    Biol Blood Marrow Transplant 8:1-8. 2002
    ..A major remaining challenge is to assess the significance of an elevated EBV load posttransplantation and to determine the indications for preemptive treatment...
  68. pmc Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor
    Aaron E Foster
    Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    J Immunother 31:500-5. 2008
    ..TGF-beta-resistant CTL had a functional advantage over unmodified CTL in the presence of TGF-beta-secreting EBV-positive lymphoma, and had enhanced antitumor activity, supporting the potential value of this countermeasure...
  69. ncbi request reprint Adoptive T-cell transfer in cancer immunotherapy
    Siok Keen Tey
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Immunol Cell Biol 84:281-9. 2006
    ....
  70. ncbi request reprint Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
    Ann M Leen
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Nat Med 12:1160-6. 2006
    ..Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host...
  71. ncbi request reprint Viral lymphomagenesis
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Curr Opin Hematol 13:254-9. 2006
    ..The presence of the viral genome in all these malignancies offers the prospect for therapeutic interventions targeting virus-encoded proteins...
  72. pmc Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease
    Catherine M Bollard
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    J Exp Med 200:1623-33. 2004
    ..One additional patient had a partial response, and five had stable disease. The performance and fate of these human tumor antigen-specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma...
  73. ncbi request reprint The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    J Immunother 27:317-27. 2004
    ..This approach is being used in a current clinical trial...
  74. ncbi request reprint Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
    Am J Transplant 5:2222-8. 2005
    ..05). These findings illustrate that frequent EBV viral load monitoring and preemptive immunosuppression modulation have an integral role in preventing PTLD in the pediatric liver transplant population...
  75. ncbi request reprint Adoptive immunotherapy for EBV-associated malignancies
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Leuk Lymphoma 46:1-10. 2005
    ..To overcome these immune evasion strategies a number of approaches have been developed including targeting CTL to subdominant EBV antigens and genetically modifying CTL to increase their potency...
  76. pmc Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
    Barbara Savoldo
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 108:2942-9. 2006
    ..These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity...
  77. pmc Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy
    C R Y Cruz
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, USA
    Clin Exp Immunol 174:89-96. 2013
    ..Our findings that T cells in CGD have a robust aspergillus CD4(+) T cell response suggest that CD4(+) T cell-based immunotherapy for this disease is unlikely to be beneficial...
  78. ncbi request reprint Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease
    M Helen Huls
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas 77030, USA
    Acta Haematol 110:149-53. 2003
    ..A number of approaches to overcome these tumor evasion strategies including targeting CTLs to the expressed antigens and genetic modification of CTLs are being evaluated...
  79. ncbi request reprint Post-transplant lymphoproliferative disorders
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Annu Rev Med 56:29-44. 2005
    ..Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies...
  80. pmc Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)
    Juan F Vera
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunother 33:305-15. 2010
    ..This bioprocess optimization increased T-cell output while decreasing the complexity and cost of CTL manufacture, making cell therapy more accessible...
  81. pmc Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
    Patrick J Hanley
    Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 114:1958-67. 2009
    ..This study is registered at www.clinicaltrials.gov as NCT00078533...
  82. ncbi request reprint Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Clin Lymphoma Myeloma 6:342-7. 2006
  83. pmc Cytotoxic T lymphocytes as immune-therapy in haematological practice
    Ann M Leen
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Br J Haematol 143:169-79. 2008
    ....
  84. ncbi request reprint Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma
    Karin C Straathof
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    J Immunol 175:4137-47. 2005
    ..These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring...
  85. ncbi request reprint A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells
    Hans Joachim Wagner
    Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Gene Ther 11:81-91. 2004
    ..Tumor-specific, Flexi-IL12-transduced EBV-specific CTL should have a functional advantage over unmodified CTL, particularly in the presence of the adverse Th2 cytokine environment produced by Hodgkin tumor cells...
  86. ncbi request reprint Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:389-93. 2006
    ..Herein we describe the use of cytokine polymorphisms and real-time quantitative polymerase chain reaction (qPCR) Epstein-Barr virus (EBV) viral load to identify patients at risk for PTLD development...
  87. pmc Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
    Raphael F Rousseau
    Center for Cell and Gene Therapy, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    Blood 107:1332-41. 2006
    ..This approach may be worthy of further study, particularly in patients with a high risk of relapse...
  88. ncbi request reprint Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals
    Barbara Savoldo
    Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunol 168:909-18. 2002
    ..In addition, our method for selecting EBV-specific CTL from naive individuals by precursor cell enrichment may be applicable to the immunotherapy of cancer patients with a low frequency of tumor- or virus-specific CTL...
  89. ncbi request reprint Treatment of Epstein-Barr virus-associated malignancies with specific T cells
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
    Adv Cancer Res 84:175-201. 2002
    ..If effective, such strategies could be applied not only to other EBV-associated malignancies, but also to a broad range of human tumors with defined tumor antigens and similar immune evasion strategies...
  90. ncbi request reprint The clone ranger?
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Mol Ther 16:1520-1. 2008
  91. ncbi request reprint Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man
    Malcolm K Brenner
    Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Ann N Y Acad Sci 996:80-8. 2003
    ..These pre-clinical and clinical results warrant further evaluation of anti-CD45 MAbs in subablative preparative regimens for stem cell transplantation...
  92. ncbi request reprint Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia
    Siddhartha Ganguly
    Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Hematol 75:48-51. 2004
    ..As there is a wide differential diagnosis for pulmonary infiltrates developing post transplant, TRALI may be under-recognized and should be considered in this setting...
  93. ncbi request reprint Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:689-94. 2006
    ..Herein, we describe the use of a novel immune assay, which quantifies the lymphocyte immune response and correlates the value to risk for EBV infection...
  94. pmc Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
    Mol Ther 17:1779-87. 2009
    ..Genetic modification of T cells with CARs specific for target antigens, expressed at too low a level to be effectively recognized by monoclonal antibodies, may allow immunotherapy to be more broadly applicable for human cancer therapy...
  95. ncbi request reprint Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation
    V Rodriguez
    Center for Cell and Gene Therapy, Texas Children s Hospital, Houston, TX, USA
    Bone Marrow Transplant 29:515-7. 2002
    ..We review possible factors contributing to the development of this syndrome in these three patients...
  96. pmc An inducible caspase 9 safety switch for T-cell therapy
    Karin C Straathof
    Center for Cell and Gene Therapy, Baylor College of Meidcine, Houston, TX 77030, USA
    Blood 105:4247-54. 2005
    ..Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies...
  97. ncbi request reprint Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 101:1905-12. 2003
    ..Targeting LMP1 in these malignancies may improve the efficacy of current adoptive immunotherapy approaches...
  98. ncbi request reprint Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity
    Catherine M Bollard
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 99:3179-87. 2002
    ..Tumor-specific CTLs expressing HATGF-betaRII-Deltacyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-beta-secreting tumors and may be of value in treatment of these diseases...

Research Grants5

  1. Enhancing T Cell Therapy of Cancer
    Helen Heslop; Fiscal Year: 2006
    ..Not Available ..
  2. Training in Cell and Gene Therapy
    Helen Heslop; Fiscal Year: 2007
    ..Taken together, these program elements especially the mentored laboratory research experience, should provide trainees with a strong foundation for translational research careers in cell and gene therapy. ..